Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2017 4
2018 2
2019 4
2020 1
2022 3
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean kenya ohnishi (1 results)?
Prostate diseases and microbiome in the prostate, gut, and urine.
Miyake M, Tatsumi Y, Ohnishi K, Fujii T, Nakai Y, Tanaka N, Fujimoto K. Miyake M, et al. Among authors: ohnishi k. Prostate Int. 2022 Jun;10(2):96-107. doi: 10.1016/j.prnil.2022.03.004. Epub 2022 Mar 29. Prostate Int. 2022. PMID: 35510078 Free PMC article. Review.
Probiotics enhances anti-tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer.
Miyake M, Oda Y, Owari T, Iida K, Ohnishi S, Fujii T, Nishimura N, Miyamoto T, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K. Miyake M, et al. Among authors: ohnishi k. Cancer Sci. 2023 Mar;114(3):1118-1130. doi: 10.1111/cas.15666. Epub 2022 Nov 30. Cancer Sci. 2023. PMID: 36398663 Free PMC article.
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.
Miyake M, Shimizu T, Oda Y, Tachibana A, Ohmori C, Itami Y, Kiba K, Tomioka A, Yamamoto H, Ohnishi K, Nishimura N, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Fujii T, Tanaka N, Fujimoto K. Miyake M, et al. Among authors: ohnishi k. Jpn J Clin Oncol. 2023 Mar 7;53(3):253-262. doi: 10.1093/jjco/hyac186. Jpn J Clin Oncol. 2023. PMID: 36484294
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group. Miyake M, et al. Among authors: ohnishi k. Jpn J Clin Oncol. 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. Jpn J Clin Oncol. 2024. PMID: 38061911
Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data.
Miyake M, Nishimura N, Shimizu T, Ohnishi M, Kuwada M, Itami Y, Inoue T, Ohnishi K, Matsumoto Y, Yoshida T, Tatsumi Y, Shinohara M, Hori S, Morizawa Y, Gotoh D, Nakai Y, Anai S, Torimoto K, Aoki K, Fujii T, Tanaka N, Fujimoto K. Miyake M, et al. Among authors: ohnishi k. Cancer Manag Res. 2022 Feb 16;14:623-635. doi: 10.2147/CMAR.S348899. eCollection 2022. Cancer Manag Res. 2022. PMID: 35210859 Free PMC article.
Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer.
Miyake M, Nishimura N, Nishioka Y, Fujii T, Oda Y, Miyamoto T, Tomizawa M, Shimizu T, Owari T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Imamura T, Fujimoto K. Miyake M, et al. Among authors: ohnishi k. Int Urol Nephrol. 2024 Mar;56(3):827-837. doi: 10.1007/s11255-023-03851-3. Epub 2023 Nov 1. Int Urol Nephrol. 2024. PMID: 37910382
19 results